News | January 21, 2011

Xience Prime Granted European Approval to Treat Lower Leg Vessels

January 20, 2011 – European CE mark approval was granted to expand the indication of Abbott’s Xience Prime everolimus-eluting coronary stent for the treatment of critical limb ischemia (CLI) or severe claudication (pain) of the lower leg. CLI is the most advanced form of peripheral artery disease (PAD) that can ultimately lead to limb amputation.

The CE mark was supported by the data generated on the company's Xience V drug-eluting stent from the DESTINY trial. The 140-patient, investigator-sponsored, randomized, controlled, multicenter trial compared the Xience V to Abbott's Multi-Link Vision bare metal stent in patients with CLI of the lower leg. Patients with lesion lengths less than 40 mm were included in this trial.

The 12-month results from DESTINY demonstrated that Xience V had significantly better patency compared to the bare metal stent at 12 months (85.2 percent Xience V vs. 54.4 percent Multi-Link Vision; p=0.0001). This difference was especially pronounced between six and 12 months, where the difference in patency rate significantly diverged, as the rate for the bare metal stent fell to nearly 50 percent while the rate for Xience V remained above 85 percent. These results demonstrated that there is a significant benefit from an everolimus eluting stent versus a bare metal stent. The data from DESTINY were presented this week at the Leipzig Interventional Course (LINC) 2011, a medical congress held in Germany for physicians treating endovascular diseases.

"The DESTINY trial demonstrates that everolimus-eluting stents result in significantly better patency at 12 months compared to bare metal stents for patients with critical limb ischemia of the lower leg, and the use of everolimus eluting stents can potentially provide significantly better outcomes for these patients," said Marc Bosiers, M.D., head of the department of vascular surgery at St. Blasius Hospital in Dendermonde, Belgium, and principal investigator of the DESTINY trial. "A drug-eluting stent such as Xience Prime provides European physicians with another treatment option for patients with short lesions in the lower leg."

The Xience Prime is commercially available in CE mark countries. It has an improved stent design and a delivery system over the Xience V, offering greater flexibility and enhanced deliverability.

For more information: www.abbottvascular.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD)| August 02, 2017
Aug.
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Overlay Init